| Trial name or title |
Metoclopramide and selective oral decontamination for avoiding pneumonia after stroke (MAPS‐2) Trial |
| Methods |
2 × 2 factorial double‐blind randomised controlled trial (treatment) |
| Participants |
Acute stroke within 9 hours of clinical onset |
| Interventions |
Metoclopramide and placebo paste
Metoclopramide and antibiotic paste
Placebo metoclopramide and antibiotic paste
Placebo metoclopramide and placebo paste |
| Outcomes |
Mortality up to the end of the study (90 days), pneumonia within 14 days, number of days of antibiotic treatment for pneumonia within the first 30 days, neurological recovery (NIHSS), disability (mRS), quality of life (EuroQol) |
| Starting date |
1 January 2017 |
| Contact information |
Christine Roffe ‐ Institute for Applied Clinical Sciences (IACS), Keele University Guy Hilton Research Centre, Thornburrow Drive, Hartshill ST4 7QB, Stoke‐on‐Trent, United Kingdom |
| Notes |
Funding: Health Technology Assessment Programme |
